We've updated our Privacy Policy to make it clearer how we use your personal data.
We use cookies to provide you with a better experience, read our Cookie Policy
EP34613
Abstract: The automated machine-learning platform covers all the main stages of early drug discovery:
▪ AI candidate drug discovery.
The platform is able to design high-quality derivatives or analogues based on known active compounds, apply deep learning to generate models, match properties and conduct synthesis feasibility analysis, and quickly find high-quality lead compounds. We have made arrangements for the development of small molecule drugs and antibody drugs.
▪ AI molecular docking.
The platform has the state-of-the-art machine learning (ML) techniques in computational docking. Our molecular dynamics (MD)-based protocols are capable in estimating the free energy of binding between the ligand and target protein.Summary: Artificial Intelligence Drug Discovery (AIDD) platform, aimed at accelerating the drug development process.References: https://aimed.protheragen.com/aidd-platform.html
▪ AI candidate drug discovery.
The platform is able to design high-quality derivatives or analogues based on known active compounds, apply deep learning to generate models, match properties and conduct synthesis feasibility analysis, and quickly find high-quality lead compounds. We have made arrangements for the development of small molecule drugs and antibody drugs.
▪ AI molecular docking.
The platform has the state-of-the-art machine learning (ML) techniques in computational docking. Our molecular dynamics (MD)-based protocols are capable in estimating the free energy of binding between the ligand and target protein.Summary: Artificial Intelligence Drug Discovery (AIDD) platform, aimed at accelerating the drug development process.References: https://aimed.protheragen.com/aidd-platform.html
Ask the author a question about this poster.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Related Posters
Protac-BOC Sciences
Alex Brown
CADD Platform
MedAI
Assessment of Long IVT mRNA Fragments with the Agilent Fragment Analyzer System
Chava Pocernich, Kyle Luttgeharm, and Steve Siembieda
Data Analysis
AI & Medicine
Quantitative mechanistic model for amyloid beta and tau protein role in synaptic plasticity
Stepan Lerner, Tatiana Karelina